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and Lelia Maria Guedes Queiroz, DDS, MSc, PhD#Purpose: Oral squamous cell carcinomas have the potential for rapid and unlimited growth. Therefore,
hypoxic tissue areas are common in these malignant tumors and contribute to cancer progression, therapy
resistance, and poor outcomes. The aim of the present study was to analyze the gene product distribution
of hypoxia-inducible factor-1a (HIF-1a) and glucose transporter-1 (GLUT-1) in cases of tongue squamous
cell carcinoma (TSCC) and to identify a preliminary correlation between these proteins and clinical staging
and Brynes’s histologic grading system (HGS).
Materials andMethods: The sample included 57 cases of TSCC. Histologic sections of 3 mmwere sub-
mitted to the immunoperoxidase method and semiquantitative analysis. The association between HIF-1a
and GLUT-1 expression in TSCC and the clinical stage and the HGS of Bryne (1998) was evaluated using the
c2 test, with the significance level set at 0.05 (a = 0.05).
Results: HIF-1a was mainly expressed in the nucleus/cytoplasm of neoplastic cells, most specimens
exhibited diffuse staining in neoplastic cells (84.2%), and focal staining was only observed in perinecrotic
areas (15.8%). GLUT-1 was expressed in the cytoplasm and membrane of malignant cells, and diffuse stain-
ing was observed in all cases. The intensity of HIF-1a expression correlated significantly with clinical stage
(P = .011) and HGS (P = .002). A significant association was observed between the distribution of HIF-1a
expression and metastasis (P = .040). Immunoexpression of GLUT-1 correlated significantly with clinical
stage (P = .002) and HGS (P = .000). GLUT-1 expression in the peripheral island was predominant
in most low-grade tumors (78.6%); in the high-grade cases, the expression prevailed in the location
center/periphery (55.8%). Comparison of the location of the tumor island in the different histologic grades
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1754 HIF-1a AND GLUT-1 IN HUMAN TONGUE CANCERConclusion: The expression of HIF and GLUT proteins within TSCC appears to be associated with dis-
ease stage, grade, and the presence of metastases. Additional studies are needed to evaluate the diagnostic
and prognostic uses of these proteins in the treatment of TSCC.
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J Oral Maxillofac Surg 73:1753-1760, 2015Oral squamous cell carcinoma (OSCC) is the most
common head and neck cancer, accounting for more
than 90% of all tumors in this region. This lesion can
involve areas not easily visualized, such as the lateral
and ventral tongue and posterior oropharynx.1 It has
a relatively high tumor recurrence rate and poor prog-
nosis, probably because it is often detected late,
frequently progresses to lymph node metastasis and
local invasion, and requires aggressive surgical inter-
vention and chemo- or radiotherapy to establish local
control.1,2 Despite recent advances in the treatment
of this lesion, the overall survival rate of patients has
remained less than 50% for many decades.2
The aggressiveness of these tumors is related to
several factors, including the histologic degree, tumor
size, involvement level of the adjacent tissues, the
presence of metastases at diagnosis, and the anatomic
location of the tumor.3 Many studies have attempted to
establish a correlation between the clinical and histo-
logic characteristics of oral cancer and its prognosis,
but the results have been unsatisfactory.4 The biologic
behavior of OSCC is uncertain; many of these tumors
have aggressive biologic behavior at the initial stages
with early regional metastases and death. However,
advanced tumors can metastasize slowly, and these
patients can remain disease free for long periods
after surgery.4,5 Therefore, additional independent
prognostic markers need to be identified to improve
the diagnosis and therapeutic regimens.6,7
The presence of neck metastases is the most impor-
tant prognostic factor for OSCC; if present, it results in
a 50% reduction in survival rates.5 The growth and
metastasis of solid tumors require the induction of
angiogenesis (ie, the formation and remodeling of
new blood vessels from a pre-existing vascular
network to ensure the delivery of oxygen, nutrients,
and growth factors to the rapidly dividing transformed
cells).8,9 One method for tumor cells to acquire the
ability to induce angiogenesis, and hence to grow
and metastasize, is through activity of the hypoxia-
inducible factor (HIF) family of transcription regula-
tors, the most important effectors of the adaptive
response to hypoxia in multicellular organisms.10
In OSCC, high levels of the HIF-1a subunit correlate
with a poor prognosis, reduced disease-specific sur-
vival, and tumor progression, including an increase
in the size of the primary lesions and lymph node
metastasis. HIF-1a is also overexpressed in most pa-
tients with SCC of the oropharynx, and this has corre-lated with a low rate of remission, a high incidence of
lymph node metastasis, and poor disease-free and
overall survival.11,12
The 2 main issues of cancer progression are insuffi-
cient glucose uptake and oxygen support if a tumor
outstrips its vasculature.13 Malignant cells can present
with an increased rate of glucose consumption, and
glucose is generally metabolized through glycolysis.
It is well-known that glucose uptake is triggered by
HIF-1a. One of themost relevant downstream proteins
activated by HIF-1a is glucose transporter-1 (GLUT-1),
a member of glucose transport molecules.14,15 The
rate of glucose transport by GLUT-1 is altered in situa-
tions in which the metabolic rate needs to be adjusted,
such as cell division (mitosis and meiosis), differentia-
tion, transformation, and nutrient starvation.8,16
Increased GLUT-1 expression correlatedwith poor sur-
vival and poor therapeutic outcomes in OSCCs on uni-
variate analysis in previous studies.17,18
Therefore, we analyzed the expression of HIF-1 and
GLUT-1 using immunohistochemistry and examined
the correlation between these proteins and the clinical
stage and Brynes’s histologic grading system (HGS).Materials and Methods
The present retrospective study analyzed 57 speci-
mens of TSCC, embedded in paraffin, and obtained
from surgical biopsies of patients who had undergone
tumor resection without previous chemotherapy and/
or radiotherapy. The Federal University of Rio Grande
do Norte research ethics committee approved the pre-
sent study (protocol no. 029/10). From the registry
files analyzed, information was obtained regarding pa-
tient gender, age, race, habits (smoker and alcohol),
clinical TNM stage of the lesion, presence or absence
of metastasis, and disease outcome (remission or
death). Metastases were demonstrated by imaging
examinations such as computed tomography or
magnetic resonance.
For histologic analysis, 5-mm-thick sections were cut
from paraffin-embedded tumor material and stained
with hematoxylin-eosin. Malignancy at the invasion
front was evaluated using the HGS proposed by
Bryne.3 For each tumor, the degree of keratinization,
nuclear pleomorphism, invasion pattern, and inflam-
matory response were analyzed semiquantitatively,
attributing scores of 1 to 4. Cases with a total score
of 4 to 8 were classified as low-grade malignancy and
VASCONCELOS ET AL 1755cases with a total score higher than 8 were classified as
high-grade malignancy.3,4
For immunohistochemistry, 3-mm-thick sections
were cut from paraffin-embedded tumor material.
The specifications of the primary antibodies (clone,
manufacturer, dilution, antigen retrieval, and incuba-
tion) are listed in Table 1. Antibodies were detected
by immunoperoxidase staining using a dextran
polymer-based signal enhancement technique
(ADVANCE, Dako, Carpinteria, CA). The reaction
was developed with diaminobenzidine as the chro-
mogen. The sections were counterstained with
Mayer’s hematoxylin and mounted in Permount
(Fisher Scientific, Fair Lawn, NJ). Negative controls
consisted of replacement of the primary antibodies
with bovine serum albumin. A colon carcinoma spec-
imen previously shown to be strongly positive for
anti–HIF-1a and erythrocyte for anti–GLUT-1 were
used as positive controls.
The specimens stained with the anti–HIF-1a and
anti–GLUT-1 antibodies were examined under a light
microscope (Olympus CH30, Olympus, Tokyo, Japan).
The slides were assessed independently by 2 investiga-
tors, who were unaware of the clinical data; any
disagreement was resolved by discussion. The staining
intensity and distribution were evaluated according to
the method of Choi et al,19 Tanaka et al,20 and Ander-
sen et al,21 to determine the immunoexpression in
stroma or parenchymal cells, the cellular location of
this staining (membrane, cytoplasm, nucleus), and
location at the periphery or in the center of the tumor
islands. Staining intensity was evaluated using scores
of 0 to 2, with 0 indicating no staining, 1, weak stain-
ing, and 2, strong staining. Cases in which more than
10% of cells were stained were defined as positive.21,22
The staining distribution was analyzed quantitatively
using the following criteria adapted from Lee et al23:
focal (<50% of immunostained cells) and diffuse
(>50% of immunostained cells).
The results were submitted to statistical analysis.
The data were originally presented in Excel format
(Office XP Professional, Microsoft, Redmond, WA)
were exported to database format and analyzed usingTable 1. SPECIFICITY, DILUTION, MANUFACTURER, ANTIGEN
Specificity Clone Manufacturer Dilutio
HIF-1a H1a67 Santa Cruz Biotechnology* 1:200
GLUT-1 SLC2A1 GeneTexy 1:400
Abbreviations: GLUT-1, glucose transporter-1; HIF-1a, hypoxia-ind
* Santa Cruz, CA.
y Irvine, CA.
Vasconcelos et al. HIF-1a and GLUT-1 in Human Tongue Cancer. J Oralthe Statistical Package for Social Sciences for Windows
XP, version 10.0 (IBM, Armonk, NY). The association
between HIF-1a and GLUT-1 expression patterns in
TSCC, and the clinical and morphologic variables
was evaluated using the c2 test, with the level of signif-
icance set at 0.05 (a = 0.05).
Results
PROFILE OF THE SAMPLE
Most patients with TSCC were men (n = 40, 70.2%)
and ranged in age from 61 to 70 years (n = 20, 35.1%).
White patients predominated in the sample (n = 32,
56.2%). Smoking and alcohol consumption were the
most frequent habits (n = 24, 42.1%), followed by pa-
tients who only smoked (n = 18, 31.6%). TNM stage III
was the most frequent (n = 22, 38.6%), followed by
stage I (n = 14, 24.6%), IV (n = 11, 19.3%), and II
(n = 10, 17.5%). With respect to outcome, tumor
remission was observed in 77.2% (n = 44) of the cases,
and 57.9% (n = 57.9%) developedmetastases (Table 2).
HIF-1a IMMUNOSTAINING
Staining for HIF-1a was positive in the stroma and
parenchyma in 100% of the TSCC cases. This protein
was expressed mainly in the nucleus/cytoplasm of
neoplastic cells (n = 44, 77.2%), followed by expres-
sion in the nucleus only (n = 12, 21.1%) and cytoplasm
(n = 1, 1.8%). In addition, most specimens exhibited
diffuse staining in the neoplastic cells (n = 48,
84.2%). Focal staining was only observed in perine-
crotic regions (n = 9, 15.8%). Evaluation of the staining
intensity revealed strong staining in 68.4% (n = 39) and
weak staining in 31.6% (n = 18). Analysis of the inva-
sion front showed expression of HIF-1a at the periph-
ery and in the center of the tumor islands and/or
sheets (P = .040; Table 3).
The intensity of HIF-1a staining correlated signifi-
cantly with the clinical stage (P = .011), with 13
(22.8%) of the 18 (31.6%) cases exhibiting weak stain-
ing being in the early disease stages (stages I and II),
and with the histologic grade of malignancy
(P = .002). In the latter case, strong staining wasRETRIEVAL, AND INCUBATION OF ANTIBODIES USED
n Antigen Retrieval Incubation
Tris/EDTA, pH 9.0, Pascal,
3 min
Overnight (18 h)
Citrate, pH 6.0, Pascal, 3 min 60 min
ucible factor-1a.
Maxillofac Surg 2015.
Table 3. ASSOCIATIONOF DISTRIBUTIONAND INTENSITYOF
AND HISTOLOGIC GRADE OF MALIGNANCY
HIF-1a
Variable
Metastasis
Absent Present
Staining distribution
Focal 1 (4.2) 8 (24.2)
Diffuse 23 (95.8) 25 (75.8)
Clinical Stage
I II III
Staining intensity
Weak 8 (57.1) 5 (50) 2 (9.1)
Strong 6 (42.9) 5 (50) 20 (90.9)
Histologic Grade
Low High
Staining intensity
Weak 9 (64.3) 9 (20.9)
Strong 5 (35.7) 34 (79.1)
Data presented as n (%).
Abbreviation: HIF-1a, hypoxia-inducible factor-1a.
Vasconcelos et al. HIF-1a and GLUT-1 in Human Tongue Cancer. J Oral
Table 2. CLINICAL AND PATHOLOGIC
CHARACTERISTICS OF PATIENTS WITH SQUAMOUS
CELL CARCINOMA OF THE TONGUE
Variable Patients (n)
Gender
Male 40 (70.2)
Female 17 (29.8)
Race
Black 14 (24.5)
Mulatto 11 (19.3)
White 32 (56.2)
Age group (yr)
31-40 3 (5.3)
41-50 6 (10.5)
51-60 18 (31.6)
61-70 20 (35.1)
71-80 7 (12.3)
81-90 3 (5.2)
Habits
Smoker 18 (31.6)
Smoker and alcohol 24 (42.1)
Nonsmoker and alcohol 1 (1.8)
Unknown 14 (24.5)
Data in parentheses are percentages.
Vasconcelos et al. HIF-1a and GLUT-1 in Human Tongue Cancer.
J Oral Maxillofac Surg 2015.
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79.1%) and weak staining in the low-grade cases
(n = 9, 64.3%; Figs 1, 2).GLUT-1 IMMUNOSTAINING
GLUT-1 was expressed in the cytoplasm and mem-
brane of the malignant cells. Diffuse staining was
observed in all cases. In the stroma, red blood cells
and some blood vessels were positive for this protein.
Most cases exhibited strong immunoexpression (n =
44, 77.2%). GLUT-1 was expressed more at the periph-
ery of the tumor islands (n = 30, 52.6%) than in the
center or periphery (n = 27, 47.4%).
The intensity of GLUT-1 staining correlated signifi-
cantly with the clinical stage (P = .002). In this respect,
11 (19.3%) of the 13 cases (22.8%) exhibiting weak
staining were in the early disease stages (stages I and
II; Fig 3). In contrast, a predominance of strong stain-
ing was observed in the more advanced disease stages
(stage III followed by stage IV; Table 4, Fig 4). A signif-
icant association was also observed between the inten-
sity of GLUT-1 staining and the histologic grade of
malignancy (P = .000), with 90.7% (n = 39) of high-
grade TSCC cases exhibiting strong staining.
With respect to the location of staining in the tumor
islands, peripheral staining was observed in mostHIF-1a STAININGWITHMETASTASIS, CLINICAL STAGE,
Total c2 P Value
4.212 .040
9 (15.78)
48 (84.2)
Total c2 P ValueIV
11.049 .011
3 (27.3) 18 (31.6)
8 (72.7) 39 (68.4)
Total c2 P Value
9.188 .002
18 (31.6)
39 (68.4)
Maxillofac Surg 2015.
FIGURE 3. Weak immunohistochemical expression of glucose
transporter-1 in a low-grade squamous cell carcinoma of the tongue
(ADVANCE horseradish peroxidase method, original magnification
200).
Vasconcelos et al. HIF-1a and GLUT-1 in Human Tongue Cancer.
J Oral Maxillofac Surg 2015.
FIGURE 1. Weak immunohistochemical expression of hypoxia-
inducible factor-1a in a high-grade squamous cell carcinoma of
the tongue (ADVANCE horseradish peroxidase method, original
magnification 200).
Vasconcelos et al. HIF-1a and GLUT-1 in Human Tongue Cancer.
J Oral Maxillofac Surg 2015.
VASCONCELOS ET AL 1757low-grade specimens (n = 11, 78.6%; Fig 4). In
contrast, central/peripheral staining predominated in
high-grade cases (n = 24, 55.8%; Table 4).
Discussion
Great variations exist in the treatment response and
prognosis (ie, patients with tumors at a similar site and
stage are treated similarly, with some patients experi-
encing prolonged survival and others dying within a
short period of regional or distant metastasis). Major
difficulties in determining the most appropriate treat-
ment of OSCC is that it is still based mainly on theFIGURE 2. Strong immunohistochemical expression of hypoxia-
inducible factor-1a in a low-grade squamous cell carcinoma of the
tongue (ADVANCE horseradish peroxidase method, original
magnification 200).
Vasconcelos et al. HIF-1a and GLUT-1 in Human Tongue Cancer.
J Oral Maxillofac Surg 2015.site and clinical tumor stage.24 Because of these diffi-
culties, additional independent prognostic markers
need to be identified to improve the diagnosis and
therapeutic regimens.6,7 It has been suggested that
hypoxia is an independent adverse prognostic factor
in patients with head and neck cancer.25 The main
transcription factor activated by hypoxia is HIF-1a,
which regulates cell metabolism as part of the cell’s
response to hypoxia. The largest functional group of
genes consistently regulated by HIF-1a are the genes
associatedwith glucose metabolism.6 HIF-1a increases
the rate of glucose uptake through the transcriptional
activation of the facultative glucose transporters
GLUT-1 and GLUT-3. Elevated expression of either
HIF1-a or GLUT-1 has been detected in many different
cancers, including head and neck tumor.14 Therefore,
we analyzed the expression of HIF-1a and GLUT-1 and
examined the correlation between these proteins and
the clinical stage and Brynes’s HGS. We were able to
show that the intensity of HIF-1a expression corre-
lated significantly with the clinical stage (P = .011)
and HGS (P = .002). A significant association was
observed between the distribution of HIF-1a staining
and metastasis (P = .040). Immunoexpression of
GLUT-1 correlated significantly with clinical stage
(P = .002) and HGS (P = .000).
Zhu et al26 and Liang et al27 reported an association
between the overexpression of HIF-1a in more
advanced OSCC and poor prognosis, lower survival
rate, and resistance to antineoplastic treatment. Roh
et al,28 analyzing the role of 5 hypoxia markers
(HIF-1a, HIF-2a, carbonic anhydrase IX, GLUT-1, and
erythropoietin receptor), found that HIF-1a is signifi-
cantly associated with disease-specific survival in stage
Table 4. ASSOCIATIONOFDISTRIBUTIONAND INTENSITYOFGLUT-1 STAININGWITHMETASTASIS, CLINICAL STAGE,
AND HISTOLOGIC GRADE OF MALIGNANCY
GLUT-1
Variable
Total c2 P Value
Metastasis
Absent Present
Staining intensity 0.952 .329
Weak 7 (29.2) 6 (18.2) 13 (22.8)
Strong 17 (70.8) 27 (81.8) 44 (77.2)
Clinical Stage
Total c2 P ValueI II III IV
Staining intensity 15.270 .002
Weak 8 (57.1) 3 (30) 2 (9.1) 0 (0) 13 (22.8)
Strong 6 (42.9) 7 (70) 20 (90.9) 11 (100) 44 (77.2)
Histologic Grade
Total c2 P ValueLow High
Staining intensity 18.136 .000
Weak 9 (64.3) 4 (9.3) 13 (22.8)
Strong 5 (35.7) 39 (90.7) 44 (77.2)
Data presented as n (%).
Abbreviation: GLUT-1, glucose transporter-1.
Vasconcelos et al. HIF-1a and GLUT-1 in Human Tongue Cancer. J Oral Maxillofac Surg 2015.
1758 HIF-1a AND GLUT-1 IN HUMAN TONGUE CANCERT2 tongue carcinoma, with a relative risk of 0.352, but
not with other clinical or pathologic parameters such
as tumor thickness, lymph node involvement, or resec-
tionmargin status. Liang et al27 reported an association
between HIF-1a overexpression in these tumors and
shorter disease-free survival.FIGURE 4. Strong immunohistochemical expression of glucose
transporter-1 in a high-grade squamous cell carcinoma of the tongue
(ADVANCE horseradish peroxidase method, original magnification
200).
Vasconcelos et al. HIF-1a and GLUT-1 in Human Tongue Cancer.
J Oral Maxillofac Surg 2015.The present study demonstrated a significant corre-
lation between the HIF-1a staining intensity and the
clinical stage and histologic grade of malignancy,
with high- and low-grade cases exhibiting strong and
weak staining, respectively. Liu et al29 observed over-
expression of HIF-1a in 69.64% of OSCC cases
analyzed, with a positive correlation with the rate of
tumor progression (ie, tumor size, lymph node metas-
tasis, histologic differentiation, clinical stage, and pres-
ence of tumor cell-lined vessels) and poor survival. In
agreement with the findings of Fillies et al30 and Lin
et al,31 most specimens studied had diffuse HIF-1a
staining, with focal staining observed in the surround-
ing necrotic areas. In addition, a significant correlation
was found with metastasis, with the presence of me-
tastases in 43.8% of the 84.2% of cases with diffuse
staining. According to Fillies et al30 and Semenza,32
the predominantly diffuse expression of HIF-1a in
tumors is related, not only to the hypoxic environ-
ment, but also to alterations in oncogenes and tumor
suppressor genes and the lack of GLUT-1 expression.
Because most of the diffuse distribution of this mole-
cule in normal epithelium is found in deep layers
when associated with keratinized areas, HIF-1a prob-
ably has a more physiologic function within this
context, participating in cell differentiation instead
of exerting a carcinogenic effect.
VASCONCELOS ET AL 1759A significant association was observed between the
expression of GLUT-1 and the clinical stage. Similar re-
sults have been reported by Kato et al33 for esophageal
carcinoma, Choi et al19 for lip SCC, and Ayala et al34 for
OSCC, highlighting the importance of the association
between this immunomarker and tumor stage and its
use as a diagnostic and prognostic marker. However,
Schrijvers et al35 found no association between the
parameters of clinical evolution and GLUT-1 staining
intensity in cases of SCC of the larynx.
Several mechanisms have been proposed to explain
the upregulation of anaerobic glycolysis in cancer, in
particular, those involving the activation of oncogenes
and/or inactivation of tumor suppressor genes that
affect glycolytic activity. For example, the c-Myc
gene is known to activate most genes that encode
glycolytic enzymes, such as lactate dehydrogenase A
and GLUT-1, which increase lactate production and
improve glucose uptake,36 respectively. According to
Vander Heiden et al,37 mutations that result in the
loss of function of succinate dehydrogenase and fuma-
rate hydrase, enzymes participating in the Krebs cycle,
cause the accumulation of succinate and fumarate in
the cytoplasm, respectively. These metabolites, in
turn, are responsible for inhibition of prolyl hydro-
lyase, an enzyme that catalyzes the hydroxylation of
HIF-1a, with a consequent increase in the concentra-
tion of this protein and signaling of a Warburg effect
emergency, thus explaining the greater expression of
GLUT-1 in malignant cells. Similarly, mutations in isoci-
trate dehydrogenase types 1 (cytoplasmic IDH1) and 2
(mitochondrial IDH2) result in the reduction of a-keto-
glutarate into 2-oxoglutarate, also contributing to the
constitutive activation of HIF-1a. These facts indicate
that GLUT-1 is involved in the complex interactions
that occur between the glucose metabolism pathways
and the mechanisms of tumor hypoxia, which are
essential for cell growth and proliferation.
Analysis of the association between the histologic
grade of malignancy and intensity of GLUT-1 staining
showed a greater frequency of high-grade and low-
grade cases exhibiting strong and weak staining,
respectively. Similarly, Kato et al33 in esophageal carci-
noma, Li et al38 in head and neck SCC, and Ohba et al12
in OSCC observed significantly weaker immunohisto-
chemical expression of this molecule in primary and
well-differentiated tumors compared with recurrent
and undifferentiated tumors. This finding suggests
that GLUT-1 can be used as a molecular target for the
diagnosis, prognosis, and adequate therapeutic choice
of head and neck SCCs.
GLUT-1 staining was detected at the periphery of
islands of neoplastic epithelial cells, in agreement
with the findings from Ohba et al.12 In addition, a sig-
nificant correlation was found between the positive
staining in the tumor islands and the histologic gradeof malignancy, with central/peripheral staining pre-
dominating in high-grade tumors. However, no corre-
lation was observed with metastasis or clinical stage.
Studies have shown that GLUT-1 is expressed mainly
at the periphery of the tumor and is absent in the cen-
ter because of a greater concentration of glycogen and
well-differentiated cells.12 These findings suggest that
the expression of GLUT-1 is inversely proportional to
the quantity of glycogen stored in the cells. Cells
located at the periphery of the tumor invasion front
require high glycolytic activity for differentiation, inva-
sion, andmetastasis. In the center of the tumor islands,
the glycogen reserves inside differentiated cells and
minimum oxygen tensionwill be sufficient tomaintain
satisfactory aerobic respiration despite the hypoxic
environment. It is believed that GLUT-1 is one of the
adaptive strategies that permit tumor growth and pro-
gression in an environment characterized by marked
oxygenation instability.12,39
GLUT-1 was expressed in the cytoplasm and mem-
brane of neoplastic cells in 100% of the TSCC cases
studied, in agreement with the findings of Kunkel
et al18 and Choi et al,19 who observed greater mem-
brane and/or cytoplasmic expression in OSCCs. In
contrast, Li et al38 andOgane et al40 reported a predom-
inance ofmembrane expression in head and neck SCC.
Demasi et al39 and Ohba et al12 observed greater
expression in the cytoplasm of neoplastic cells of
mucoepidermoid carcinoma and OSCC, respectively.
These findings suggest greater transcription of GLUT-
1 during cell growth and proliferation, which is stored
in intracytoplasmic endosomes and expressed on the
plasma membrane surface, depending on the need
for higher energy uptake by neoplastic cells.16
The significance of induction of GLUT-1 expression
for neoplastic transformation of the epithelium is not
well established. Schrijvers et al35 and Zhu et al26
demonstrated the coexpression of GLUT-1 and HIF-
1a in head and neck SCC cases, supporting the hypoth-
esis that GLUT-1 is expressed in response to tissue
hypoxia. However, Pedersen et al41 suggested that
GLUT-1 expression is a constitutive characteristic of
the malignant phenotype and is induced by Ras and
Src oncogenes. In the present study, low-grade cases
or cases in the early stages of disease (stage I and II) ex-
hibited strong staining for these markers of hypoxia. In
contrast, high-grade cases or cases in the late disease
stages (stage III and IV) showed weak expression.
In conclusion, our study has provided additional ev-
idence that hypoxia-regulated proteins, such as HIF-1a
and GLUT-1, can be used in the clinic to infer the pres-
ence of hypoxia in tumors. However, the type of
scoring system used to determine the predictive qual-
ity of these hypoxia markers requires future studies of
their combined use in a variety of clinical situations.
The results of the present study suggest that the
1760 HIF-1a AND GLUT-1 IN HUMAN TONGUE CANCERexpression of HIF and GLUT proteins within TSCC ap-
pears to be associated with disease stage, grade, and
the presence of metastases. Furthermore, we empha-
size the difficulty in standardizing parameters that
can be universally used as prognostic markers. There-
fore, additional studies are required to validate the util-
ity of these proteins as independent prognostic
markers for patients with OSCC.
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